A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma

• Neha Korde,
• Mattias Carlsten,
• Min-Jung Lee,
• Alex Minter,
• Esther Tan,
• Mary Kwok,
• Elisabet Manasanch,
• Manisha Bhutani,
• Nishant Tageja,
• Mark Roschewski,
• Adriana Zingone,
• Rene Costello,
• Marcia Mulquin,
• Diamond Zuchlinski,
• Irina Maric,
• Katherine R. Calvo,
• Raul Braylan,
• Prashant Tembhare,
• Constance Yuan,
• Maryalice Stetler-Stevenson,
• Jane Trepel,
• Richard Childs,
• Ola Landgren

Affiliations

Neha Korde

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Mattias Carlsten

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Min-Jung Lee

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Alex Minter

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;Walter Reed National Military Medical Center, National Institutes of Health, Bethesda, MD, USA

Esther Tan

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;Walter Reed National Military Medical Center, National Institutes of Health, Bethesda, MD, USA

Mary Kwok

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;Walter Reed National Military Medical Center, National Institutes of Health, Bethesda, MD, USA

Elisabet Manasanch

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Manisha Bhutani

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Nishant Tageja

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Mark Roschewski

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Adriana Zingone

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Rene Costello

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Marcia Mulquin

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Diamond Zuchlinski

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Irina Maric

Dept. of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA

Katherine R. Calvo

Dept. of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA

Raul Braylan

Dept. of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA

Prashant Tembhare

Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Constance Yuan

Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Maryalice Stetler-Stevenson

Flow Cytometry Unit, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Jane Trepel

Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Richard Childs

Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA

Ola Landgren

Multiple Myeloma Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA;Myeloma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA